$KALV Reports Positive Results for KVD900 Phase 2

10 de fev. de 2021

KALV KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

– Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) –

– KVD900 Generally Safe and Well-Tolerated –

There were no serious adverse events reported in the trial and no patients withdrew due to adverse events.

finance.yahoo.com/news/kalvista-pharmaceuticals-reports-positive-results-113000067.html